Similar articles

• Spasticity treatment facilitates direct care delivery for adults with profound intellectual disability.

  Charles PD, Gill CE, Taylor HM, Putman MS, Blair CR, Roberts AG, Ayers GD, Konrad PE. Charles PD, et al. Mov Disord. 2010 Mar 15;25(4):466-73. doi: 10.1002/mds.22995. Mov Disord. 2010. PMID: 20131401
• Managing spasticity with drugs.

  Simon O, Yelnik AP. Simon O, et al. Eur J Phys Rehabil Med. 2010 Sep;46(3):401-10. Eur J Phys Rehabil Med. 2010. PMID: 20927006 Review.
• Botulinum toxin type A with oral baclofen versus oral tizanidine: a nonrandomized pilot comparison in patients with cerebral palsy and spastic equinus foot deformity.

  Dai AI, Wasay M, Awan S. Dai AI, et al. J Child Neurol. 2008 Dec;23(12):1464-6. doi: 10.1177/0883073808319074. J Child Neurol. 2008. PMID: 19073853 Clinical Trial.
• New approaches to managing spasticity in children with cerebral palsy.

  Im D, McDonald CM. Im D, et al. West J Med. 1997 Apr;166(4):271. West J Med. 1997. PMID: 9168686 Free PMC article. No abstract available.
• [Botulinum toxin type A in the treatment plan for cerebral palsy].

  Strobl W. Strobl W. Wien Klin Wochenschr. 2001;113 Suppl 4:30-5. Wien Klin Wochenschr. 2001. PMID: 15506050 Review. German.